DiversiTrials

If you like seeing these Clinical Trial Diversity Scorecards, go and give CARER Group a follow. Their website also has an entire collection!

Leqselvi, a Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata (a common autoimmune disease causing sudden hair loss on the scalp, face and sometimes other areas of the the body) was approved by the FDA in July, 2024. The overall Grade is C. There is poor representation of Hispanic ethnicity (D Grade). Also the pivotal trials excluded participants over 65 years of age. 

Piasky, a complement C5 inhibitor indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) was approved by the FDA in June, 2024. The overall grade is C with poor Black and Hispanic representation in the trial (both D grade). There was no enrollment in the US and 2/3 of the enrollment was from Asia therefore the Asian representation was good (B grade).  

Voranigo, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma was approved by the FDA in August 2024. These are rare brain tumors. The overall Grade is C with good representation of females (Grade A) and poor representation of those 65 yo and older (Grade D). Of note the FDA made the following comment in their review. The FDA PMC/PMR checklist for trial diversity for Voranigo indicated the need for PMC/PMR. FDA review " The distribution of race was generally similar between arms and generally representative of the United States population; Black patients were likely under-represented, though there is a slight White predominance for this disease. Of the overall study population, only 3 Black/African American patients were enrolled. The distribution likely underrepresents the incidence of IDH-mutant Grade 2 glioma in this group and possibly other racial and ethnic minority groups. Despite these limitations, and given the targeted mechanism of vorasidenib, FDA agrees that the submitted data is supportive of the proposed indication for the US population.  "

And this 👇👇👇 Great Texas congressional meeting- August 19, 2024

This 👇👇👇Thanks to Lebanon Times, September issue 2024

All great things come to an end. Lets wrap this up DiversiStyle! Join the DiversiTeam one last time as we finalize our mini-series dedicated to reviewing the FDA's Draft Diversity Action Plan (#DAP) guidance. Bring your voice. Speak up. And lets advocate for positive and inclusive research. #Diversity; #ClinicalTrials; #ClinicalResearch; #DAPandMe; #DiversiTrials https://lnkd.in/gZ9Er-kp

We are thrilled to announce our collaboration with the Clinical Research Learning Network! Together, we are dedicated to enhancing patient education and promoting inclusivity in clinical research. As part of this partnership, we are proud to support the creation of a #FREE module for patient education. This module is designed to empower patients with the knowledge they need to make informed decisions about their participation in clinical research. But that’s not all! We have been working closely with the Clinical Research Learning Network to ensure that all courses, both for patients and professionals, have been translated into #Spanish, #Arabic, and #Hindi. This initiative reflects our shared commitment to breaking down language barriers and making vital information accessible to diverse communities! Additionally, The Clinical Research Learning Network also offers a variety of modules for industry professionals, including comprehensive training on Good Clinical Practice (#GCP). These courses are essential for ensuring that clinical research is conducted ethically and effectively. For more information about this initiative and to explore the courses, visit: https://lnkd.in/ec7hEUws Together, we are paving the way for a more inclusive and informed future in clinical research! ❤️🌍 #DiversiTrials #CRLN #PatientEducation #IndustryTraining #GCP #InclusiveResearch #ClinicalResearch #GlobalHealth #Partnerships Mitchell Hilbe Hadi Danawi, PhD, MPH د. هادي ضناوي Daniel Fox, MPH, PhD Joshua W.

Discover why digital patient recruitment may not be the best approach for engaging underrepresented minorities like Arab Americans and South Asian Americans in clinical trials. #ClinicalTrials #HealthEquity #DiversityInResearch #DigitalRecruitment Hadi Danawi, PhD, MPH د. هادي ضناوي Arab Board for Clinical Research Habibis United Research MENASA Clinical Research Summit DiversiTrials

DiversiTrials Arab Board for Clinical Research MENASA Clinical Research Summit Habibis United Research Sincere Thanks for Hosting and Endorsing the DiversiTrials and Habibis United Research Meeting at the Congressional Office. Dear Dr. Lalani and Team, I hope this message finds you well. On behalf of DiversiTrials and Habibis United Research, I want to express our deepest gratitude to you and your entire team for endorsing and hosting the recent meeting at your office in Sugar Land, TX, on August 19, 2024. The event, which focused on championing minority equity in clinical trials, was an overwhelming success, thanks in large part to your support and hospitality. The meeting was very well received, drawing significant attendance both in person and virtually. The level of engagement from participants underscored the importance of this crucial topic. Your commitment to addressing the disparities in clinical research, particularly as they affect Arab Americans, South Asian Americans, and other underrepresented populations, is inspiring. Your leadership in this area is helping to pave the way for more inclusive and equitable healthcare outcomes for all. We sincerely appreciate the time, effort, and resources that you and your team dedicated to making this event a success. Your endorsement of this cause amplifies the impact of our collective work and highlights the critical role that legislative and community leaders play in advancing health equity. As we look to the future, we are excited about the prospect of continuing our collaboration. We are particularly looking forward to the upcoming Middle Eastern, North Africans, and South Asians (MENASA) Summit, organized by DiversiTrials and Habibis United Research, to be held on April 19, 2025, at the United Way of Greater Houston, TX. With your ongoing support, we are confident that we can continue to make meaningful strides in advocating for the inclusion of all communities in clinical trials. Thank you once again for your partnership and for championing the cause of minority equity in clinical trials. We greatly look forward to working together on future initiatives. Warm regards, Hadi Danawi